Biotron’s Managing Director, Michelle Miller, said;“The results from the extended, repeat Study 2 confirm the results from Study 1, showing aclear clinical benefit from the treatment with BIT225.Supported by these results, and in consultation with USA ba sed advisors and consultants,Biotron has submitted a proposal to the USA Food and Drug Administration (FDA) to conducta human clinical trial to asse ss the efficacy of BIT225 for th e treatment of COVID-19 underthe Coronavirus Treatment Acceleration Program, a special emergency program for potentialcoronavirus therapies.Funding the clinical development of BIT225 for this indication will be sought from potentialpartners and non-equity funding sources.”
